Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UX701 gene therapy study in adults with Wilson disease
2022-502873-40-00Phase 2Authorised
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Jun 2022
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of rivunatpagene miziparvovec in Wilson disease (WD) (3 arms), sponsored by Ultragenyx Pharmaceutical Inc. Planned start Jun 2022; status: authorised.
02
Drugs
rivunatpagene miziparvovec
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2022-502873-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502873-40-00.